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The Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR) system 
is an adaptive immune system utilized by prokaryotes to preserve their genome against 
invasive nucleic acid. CRISPR-derived RNA (crRNA) and CRISPR associated (Cas) 
proteins form an effector complex that degrades foreign genetic elements and is the basis 
of this prokaryotic defense system. The CRISPR Type III-B effector complex, also 
referred to as the Cmr complex, is composed of 6 protein subunits (Cmr1-6) and a 
crRNA. It has been shown to cleave ssRNA in vitro and degrade transcriptionally active 
DNA in vivo. To understand the mechanism of this activity, we undertook a biochemical 
analysis of the Cmr complex to determine how it cleaves nucleic acid. 
 
We have been able to recombinantly express and purify the individual Cmr 
subunits of Thermotoga maritima MSB8, to form the Cmr complex with a short crRNA in 
vitro. Using pull-down assays we demonstrate that Cmr proteins from Thermotoga 
maritima assemble into a Cmr complex with the same subunit interactions as those 
observed for Cmr complexes from other species. Furthermore, we have reconstituted 
CRISPR-mediated degradation of RNA in vitro. Analysis of this activity demonstrates 
the preference for cleavage of ssRNA at 6 nucleotide intervals and the dependence on the 
2’ hydroxyl adjacent to the scissile phosphate for cleavage.  
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We also report ssDNA cleavage activity by the Cmr complex, which was 
previously unknown. Cleavage is observed only at thymidine nucleotides and is 
dependent upon the presence of target RNA complementary to the crRNA of the 
complex. We also demonstrate that as complementary target RNA is degraded, DNA 
activity is turned off. We mapped the active site for ssDNA cleavage to the HD domain 
of the Cmr2 subunit. 
 
Our in vitro results are consistent with transcription-coupled DNA targeting by 
the Cmr complex. This study further resolves the ambiguity in activities reported for 
Type III systems and supports a unified mechanism for all Type III systems in which 







Thesis Advisor: Dr. Scott Bailey 
Thesis Readers: Dr. Sean Prigge, Dr. Paul Miller, Dr. Herschel Wade, and Dr. Andrew 
Pekosz 




There have been those that have guided me and taught me science and those that 
have supported and enabled me to pursue my love of it. I am so fortunate for all these 
people I have met on my journey to and through graduate school, and I hope they 
understand how much they mean to me.  
 
First and foremost, I would like to thank my advisor, Scott Bailey, for accepting 
me into his lab and guiding me through a challenging project. I will always cherish our 
stimulating scientific conversations lasting hours and appreciate your patience with me. I 
am also indebted to my thesis committee members: Roger McMacken, Paul Miller, Sean 
Prigge and Herschel Wade. Thank you for your support throughout my graduate career, 
and for the myriad conversations about science and life after graduate school. 
 
I would also like to thank Brian Learn and past lab members Gabriel Brandt and 
Sabin Mulepati for their advice on experiments and presentations. I am thankful to Jürgen 
Bosch, Michael Matunis and Pierre Coulombe for allowing me to use their equipment in 
times of need. I am appreciative to all the members of the Bailey and Bosch labs over the 
years that have enriched my social and professional life and have contributed to my work. 
I am also thankful to the members of my BMB class (Cathy Chen, Daisy Colón-López, 
Shaina Palmere, Eric Wier, Lauren McGinnis, Dolly Singh and Casey Daniels) for 
helping me get through our first year classes and for numerous discussions about 
	 v	
experiments and careers. In addition, I would like to thank Cathy for being an awesome 
lab partner, Daisy and Shaina for all the laughs and Eric for being a great roommate.  
 
There are so many wonderful people that helped me get to Johns Hopkins. Most 
importantly is my undergraduate advisor, Filomena Califano. She taught me to be 
passionate about science and proffered so many opportunities for my scientific 
advancement. Then there is José Rodriguez, who gave me my first opportunity to work in 
a lab professionally and is the most productive person I know. I would like to thank 
Terrence Buck who made it all happen and Laura Barrio who is great friend and 
inspiration for me.  
 
Last, I would like to profusely thank my family for supporting me. Thank you to 
my mother, Candida Vasquez, for telling me I can do anything I want and saying it with 
enough conviction to keep me motivated. Thanks to my older siblings Grace and John 
that have served as great role models and have given me awesome nieces and nephews. I 
would also like to thank my fiancé’s mother, Maria Meregildo, and brother’s Ismael and 
Fernando Caraballo for their love and support. Finally, I can’t imagine graduate school 
let alone life without my fiancé, Lilibeth Caraballo.  She has been my rock through all the 
ups and downs and the one person I could count on in times of need. Her unwavering 





Table of Contents  
 
Title Page………………………………………………………………………………….i  
 




Table of contents………………………………………………………………………...vi 
 
List of Figures……………………………………………………………..……....……..ix 
 
List of Tables………………………..………………………………………..……...…..xi 
 
Chapter 1 Introduction………………………………………………………1 
   Genome diversification and preservation in prokaryotes……..2 
   The CRISPR immune system…………………………………...4 
Structure of CRISPR loci………………………………………..6 
The different CRISPR systems……………………………..…...7 








Chapter 2  Making the Type III-B complex…………………………….....25 
   Reconstitution of the Cmr complex from Thermotoga  
   Maritima……...……………………………………………….....26 
   Materials and methods…………………………………………28 
   Figures…………………………………………………………...30 
 
Chapter 3  RNA degradation by the CRISPR Type III-B complex……...34 
   The Thermotoga maritima Cmr complex cleaves ssRNA….....35 
   Materials and methods…………………………………………39 
   Figures…………………………………………………………...41 
 
Chapter 4  DNA degradation by the CRISPR Type III-B complex……...48 
   DNA cleavage by the Cmr complex……………………………49 
   RNA target binding licenses ssDNA cleavage………………...50 
   Sequence specificity for the ssDNA target…………………….52 
Cleavage of ssDNA in the context of dsDNA………………….53 
Mutations in the HD domain of Cmr2 abolish ssDNA 
Cleavage…………………………………………………………54 
Materials and methods…………………………………………56 
	 viii	
   Figures…………………………………………………………...58 
 



















List of Figures 
 
Figure 1.1  An overview of the viral life cycle and bacterial defense strategies……..20 
Figure 1.2  Representative CRISPR loci in a Prokaryotic Chromosome…………….21 
Figure 1.3  Diversity of Cas proteins………………………………………………...22 
Figure 1.4  Type I, II, and III CRISPR systems……………………………………...23 
Figure 1.5  The CRISPR immune system has three distinct stages………………….24 
Figure 2.1  Schematic representation of CRISPR loci on the chromosome of 
Thermotoga maritima MSB8…………………………………………….30 
Figure 2.2  Assembly of the T. maritima Cmr complex……………………………...31 
Figure 2.3  Pairwise interactions of recombinantly purified Cmr subunits…………..32 
Figure 2.4  Interactions within the Cmr complex…………………………………….33 
Figure 3.1.  The T. maritima Cmr complex cleaves ssRNA………………………….41 
Figure 3.2  RNA cleavage by the Cmr complex is metal dependent………………...43 
Figure 3.3  Determination of the chemical species generated after cleavage by the 
CMR complex……………………………………………………………44 
Figure 3.4  Determinants for RNA cleavage by the T. maritima Cmr Complex…….45 
Figure 4.1  DNA cleavage by the Cmr complex…………………………………….58 




Figure 4.4  Mutation of the D26A residue in Cmr4 eliminates ssRNA cleavage and 
complementarity by the target RNA to the crRNA at the 5’ handle 
diminishes ssDNA activity………………………………………………61 
Figure 4.5  RNA turnover by the Cmr complex……………………………………...63 
Figure 4.6  Determinants for DNA cleavage by the T. maritima Cmr complex……..65  
Figure 4.7  Effects of mutations in Cmr2…………………………………………….67 
















List of Tables 
Table 3.1  Sequence of RNA oligonucleotides used in assays……………………...47  

























Genome diversification and preservation in prokaryotes 
 
Prokaryotes are exceptionally diverse, and attempts to quantify their diversity is 
understood to be beyond practical calculation (Doolittle & Zhaxybayeva 2009; Curtis et 
al. 2002; Whitman et al. 1998). The diversity of bacteria and archaea has allowed them to 
colonize every habitat and represent the largest component of biomass on earth (Suttle 
2005).  This surfeit of genetic variability is partially attributed to their ability to exchange 
genetic information through a process known as horizontal gene transfer (HGT).  HGT, 
specifically involves swapping of genetic material by organisms that are not in a parent-
progeny relationship (Soucy et al. 2015).  In prokaryotes, the three best-characterized 
mechanisms of HGT are conjugation, transformation, and transduction (Thomas & 
Nielsen 2005). Conjugation requires contact between a donor and recipient cell with a 
pilus, through which genetic material is exchanged. Transformation is the absorption of 
extracellular genetic material from the environment. Lastly, transduction is the delivery 
of genetic material into cells via infection by bacteriophages.  For example, the 
hyperthermophilic bacteria Thermotoga maritima is known to contain >20% open 
reading frames that are archaeal in origin (Nelson et al. 1999). To account for this 
observation, it is presumed that Thermotoga maritima acquired these genes through HGT 
from archaeal taxa subsequent to the Archaea–Bacteria split.  
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For transferred genes to successfully integrate, a requisite is that they do not harm 
the recipient. The acquired genetic information may be beneficial or neutral. If neutral, it 
may remain so and be lost over time or it may prove to be beneficial later on due to 
selection. Equally, this genetic information could be detrimental to the individual host 
and/or the entire colony. A major reservoir of harmful genetic information are viruses, 
which outnumber prokaryotes and kill up to 50% of the bacteria produced everyday 
(Wommack & Colwell 2000; Breitbart & Rohwer 2005).  Due to the incessant threat 
viruses prose, prokaryotes have developed various mechanisms to impede the integration 
and propagation of harmful genetic information. These mechanisms neutralize the virus’s 
effort to assume their parasitic relationship with prokaryotes at every step, including: 
attachment, nucleic acid injection, replication, transcription, viral particle assembly and 
lysis (Figure 1.1A) (Seed 2015). Specifically, the mechanisms are absorption inhibition, 
restriction-modification, abortive infection and CRISPR (Figure 1.1B) (Forde & 
Fitzgerald 1999; Bickle & Krüger 1993; Chopin et al. 2005; Rath et al. 2015). 
 
Of the defense systems listed above, two specifically target invasive nucleic acid: 
restriction-modification (R-M) and CRISPR. Classically, R-M systems are comprised of 
a restriction endonuclease (RE) and a cognate methyltransferase. The methyltransferase 
will methylate self-DNA at specific sequences, whereas foreign DNA is unmodified. The 
basis of this system is methylation status at specific DNA sequences due to the REs 
activity of degrading unmethylated DNA at specific sites (Tock & Dryden 2005).  The R-
M system is supplemented by CRISPR to degrade foreign nucleic and protect prokaryotes 
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from harmful genetic elements. CRISPR, which stands for Clustered Regularly 
Interspaced Short Palindromic Repeats, is a recently discovered prokaryotic immune 
system that uses ribonucleoprotein complexes to bind specifically to foreign nucleic acid 
sequences and degrade them.  
 
The CRISPR immune system 
 
CRISPR is found in 87% of archaeal and 50% of bacterial species that have been 
sequenced (Makarova et al. 2015). The hallmarks of a CRISPR system in prokaryotic 
genomes are arrays of short repeating DNA sequences separated by similarly sized 
variable spacer sequences (Mojica et al. 2000). These repeating sequences were first 
identified in the genome of Escherichia coli in 1987, yet their function was unknown 
(Ishino et al. 1987). As more prokaryotic genomes were sequenced, the prevalence of 
these repeats became evident. In addition, it was noted that the variable spacer sequences 
were homologous to DNA from plasmids and viruses (Mojica et al. 2005; Pourcel et al. 
2005; Bolotin et al. 2005). This observation implied the spacers were of extra-
chromosomal origin and could be a genetic record of past infections. Furthermore, these 
sequences could serve as an immune system by preventing foreign DNA expression 
(Bolotin et al. 2005). In 2007, the first direct proof of this postulated immune activity was 
confirmed in Streptococcus thermophilus (Barrangou et al. 2007).  It was demonstrated 
that upon bacteriophage infection S. thermophilus acquired new spacer sequences that 
were complementary to the bacteriophage genome.  
	 5	
 
 With the function of CRISPR established, studies were then conducted to 
understand the molecular mechanism by which the system operates. Using in silico 
analysis it was observed that CRISPR loci were flanked by genes unique only to 
prokaryotes containing CRISPR (Jansen et al. 2002). These first CRISPR-associated 
(Cas) genes, of which there were four, were named cas1-4. Of note, Jansen et al. and 
Mojica et al. were the first to standardize the nomenclature of this field and settled upon 
CRISPR for the DNA arrays and Cas for the proteins encoded by the flanking genes. 
Following the first four cas genes, a large number of other genes were identified and 
grouped into putative functional subtypes based on sequence homology (Haft et al. 2005; 
Makarova et al. 2006).  The function of these cas genes was confirmed after it was 
demonstrated that the proteins they encode process RNA transcribed from CRISPR loci 
(crRNA) and form a large multi-protein complex with the crRNA, that silences foreign 
DNA (Brouns et al. 2008).  The crRNA functions like a guide and binds complementary 
sequences, while the Cas proteins catalyze the degradation of foreign nucleic acid.  
 
 With these results, it is apparent that the CRISPR system must have a mechanism 
to acquire new spacers, generate crRNAs and then use Cas proteins to degrade foreign 
nucleic acid. As such, the CRISPR immune response has been divided into three distinct 
stages: (i) adaption, (ii) crRNA biogenesis, and (iii) interference (Makarova et al. 2011). 
In addition, the large number of cas genes flanking CRISPR loci have been divided into 
functional groups based upon sequence homology and biochemical function.  
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Structure of CRISPR loci 
 
 CRISPR loci consist of short repeating DNA sequences interspaced by variable 
invader sequences called spacers (Figure 1.2). The size of the repeats ranges from 24-47 
base pairs and a large subset of them are palindromic (Grissa et al. 2007).  When 
transcribed, these palindromic sequences can form secondary structures, such as hairpins 
(Mojica et al. 2005). The variable spacers range in size from 20-58 base pairs and are 
typically derived from extra-chromosomal sources, yet it has been shown that a small 
subset of spacers are derived from the host chromosome (Mojica et al. 2000; Stern et al. 
2010). The longest CRISPR loci was found to contain 374 repeat-spacer sequences, and a 
single prokaryotic chromosome can carry between 1-18 different CRISPR loci 
(Marraffini & Sontheimer 2010a; Pourcel et al. 2005). The sequence of the repeats at 
different CRISPR loci for a given organism is typically very similar. Directly upstream to 
a CRISPR array is the leader sequence, which is A-T rich. The leader sequence also 
consists of promoter elements that control transcription of the CRISPR loci. Acquisition 
of new spacers always occurs near to the leader region. This results in polarity, whereby 
the most recently incorporated spacers are proximal to the leader sequence and older 
spacers are distal (Pourcel et al. 2005). As mentioned above, there is a finite amount of 
spacers that can be incorporated and those oldest are lost. Additionally, because of the 
polarity a CRISPR locus can serve as a chronological history of the infections a particular 
host has been subjected to.  
	 7	
 
The different CRISPR systems 
 
 Based on the overall sequence conservation of cas genes, the CRISPR system has 
been divided into five main types- I, II, III, IV, and V (Figure 1.3) (Makarova et al. 
2015). This classification is the latest on the state of CRISPR organization, which has 
undergone several updates as new genes are discovered (Haft et al. 2005; Makarova et al. 
2006; Makarova et al. 2011). Due to the extreme diversity of cas genes and the difficulty 
of generating simple phylogenetic classifications because of the dynamic nature of 
prokaryotic genomes, we can expect further updates to the organization of CRISPR 
systems in the future. I will focus on types I, II, and III, which are better characterized, to 
give a survey of their activity through the three stages of the CRISPR immune response 
(Figure 1.4). 
 
 The CRISPR type I system is the most prevalent and is identified in prokaryotic 
genomes through the presence of its signature gene cas3 (Makarova et al. 2011). The 
Cas3 protein is involved in the interference step and it has been demonstrated to degrade 
foreign DNA (Brouns et al. 2008; Jore et al. 2011; Semenova et al. 2011). Cas3 usually 
consists of an N-terminal nuclease domain and a C-terminal helicase domain, although 
the two domains can sometime exist as two separate genes. The nuclease domain and 
specifically its histidine-aspartate motif have been shown to be responsible for cleavage 
of ssDNA (Mulepati & Bailey 2011; Sinkunas et al. 2011). The type I system can be 
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further divided into seven subtypes (I-A to I-F and IU), each with different sets of Cas 
proteins that form large multi-protein complexes with the crRNA. These complexes help 
process the crRNA and then bind to dsDNA that matches the crRNA it is carrying. Upon 
binding the target dsDNA, the complexes form R-loops and Cas3 is recruited to degrade 
the exposed ssDNA.  
 
 The CRISPR type II system is only found in bacteria and its signature gene is 
cas9 (Makarova et al. 2011). The type II system, unlike types I or III, requires only one 
protein, Cas9, to identify and degrade foreign sequences. Cas9 contains two well-
conserved domains, HNH and RuvC, both of which are involved in processing crRNA 
and cleaving target DNA. The type II system is unique in that, it requires a trans-
activating crRNA (tracrRNA) and endogenous RNase III to process crRNA (Deltcheva et 
al. 2011). The type II effector complex, which includes Cas9, crRNA, and tracrRNA, can 
perform dsDNA cleavage. Using the crRNA as a guide, Cas9 binds to dsDNA and 
cleaves the strand complementary to the crRNA with its HNH nuclease domain and 
cleaves the non-complementary strand with its RuvC nuclease domain (Osawa et al. 
2015). The type II system is further divided into three subtypes (II-A to II-C). 
 
The CRISPR type III system is more abundant in archaea than bacteria and is 
composed of four subtypes (III-A to III-D) (Staals et al. 2014; Tamulaitis et al. 2014). 
The signature gene is cas10 and it is involved in the interference step. Type III systems 
are similar to type I, in that they form large multi-protein complexes that bind crRNA and 
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protein crystal diffraction studies show that they are structurally comparable (Deng et al. 
2013; Goldberg et al. 2014; Samai et al. 2015). Unlike the type I complexes, the type III 
complexes are not involved in the crRNA-processing step although they may play a role 
in secondary processing (Zhang et al. 2012). A separate protein that is not part of the 
effector complex, Cas6, performs primary crRNA processing in the type III system 
(Samai et al. 2015). Additionally, the multi-protein complexes of type III systems are 
sufficient to cleave their targets and don’t require the recruitment of additional factors, 
like Cas3 in the type I system (Taylor et al. 2015). The type III system has been 
demonstrated to cleave both DNA and RNA (Mulepati & Bailey 2011). 
 
It is worth mentioning that a single prokaryote may carry various subtypes 
belonging to the various CRISPR types.  In addition, different effector complexes can use 
the same spacers (Majumdar et al. 2015), although they will be processed differently 
based on the CRISPR system type (Carte et al. 2014).  
 
The three stages of CRISPR 
 
 The CRISPR system has three stages: (i) adaption, (ii) crRNA biogenesis, and (iii) 
interference (Figure 1.5). The adaption stage is conserved among all CRISPR types, but 
the crRNA biogenesis and interference stages are quite different. In addition, there is 





The adaption stage provides prokaryotes with the genetic memory to mount an 
immune response when challenged by invasive genetic elements. The acquisition of new 
spacers has been demonstrated for different organisms containing different CRISPR 
arrays and subtypes, indicating a common mechanism between all organisms containing 
CRISPR (Makarova et al. 2011; Makarova et al. 2015). There are two methods to acquire 
spacers: naïve, when the invader is encountered for the first time, and primed, when there 
is a pre-existing record of the invader in the CRISPR loci.  In both methods, the Cas1 and 
Cas2 proteins are key factors in spacer integration. This function has been confirmed by 
demonstrating that they are sufficient for integration to occur in the absence of all other 
Cas proteins and that they directly interact with CRISPR DNA (Jackson & Wiedenheft 
2015).  In addition, Cas1 and Cas2 are considered essential genes for CRISPR because 
they are ubiquitously found in all prokaryotes containing CRISPR. However, other Cas 
proteins have been implicated including Cas9, Csn2, and Cas4 (Mulepati & Bailey 2011). 
The role of these proteins and other Cas proteins in spacer integration is not directly 
known.  
 
The invader sequence selected for acquisition into a CRISPR array is referred to 
as a protospacer. Protospacers are small (20-58 base pairs) relative to the entire genome 
of the invader to be surveyed. In silico analysis has shown that a 2-5 base pair sequence 
adjacent to the protospacers in the invader genome are conserved within a species 
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(Sinkunas et al. 2013). This sequence, called a protospacer adjacent motif (PAM), has 
been shown to be essential for spacer acquisition (Makarova et al. 2012). The PAM is 
also important for the interference stage to help find target sequences for degradation. In 
addition to the PAM, other DNA motifs that help select protospacers for integration have 
been identified including a 2 base pair sequence called acquisition affecting motif (AAM) 
and Chi sites which are enriched in high copy number invasive plasmids and viruses 
(Hatoum-Aslan et al. 2014).  
 
During primed acquisition of invader sequences, effector complexes that are 
typically associated with the silencing stage, bind to foreign nucleic acid protospacers 
though the complementarity between the guide crRNA and the target may not be perfect. 
The effector complex will not be able to degrade the foreign nucleic acid because of the 
imperfect match in sequence but this process leads to the recruitment of other Cas 
proteins, resulting in an accelerated uptake of spacers from the invader. This is 
advantageous because multiple spacers to the same invader provide increased resistance 
and make it more difficult for the target to evolve escape mutants, as several sites would 
need to be changed simultaneously. The process of primed acquisition has been 
demonstrated in the type I-E system of E. coli (Deng et al. 2013).  
 
Mechanistically to integrate a spacer, the first repeat sequence proximal to the 
leader sequence serves as a template for the synthesis of a new repeat and the spacer, 
cleaved by Cas1-Cas2, is integrated between them (Hale et al. 2009; Hatoum-Aslan et al. 
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2014). The palindromic nature of CRISPR repeats leads to their adopting a cruciform 
structure, which is important to determine the position and direction of spacer integration 
into the array (Hale et al. 2009; Zhang et al. 2012; Staals et al. 2013; Staals et al. 2014; 
Tamulaitis et al. 2014; Samai et al. 2015). Taken together, spacer integration is 
orchestrated by both the sequence and structure of CRISPR loci. Occasional deletion of 
spacers is required to limit the size of the CRISPR, but there is little knowledge of the 




crRNA biogenesis involves the transcription CRISPR loci, which generates a long 
RNA that is then processed into smaller functional crRNAs that can guide effector 
complexes to their targets. The processed crRNAs are composed of a single spacer 
flanked by partial repeats. Expression of the CRISPR locus is driven by the leader 
sequence, which is A-T rich and consist of promoter elements (Samai et al. 2015). How 
CRISPR expression is induced is still not clear, but there is evidence that there are 
transcriptional activators (Makarova et al. 2012). In addition, envelop stress has been 
shown to induce expression, this is significant because when viruses bind to prokaryotic 




It has been demonstrated that even when different CRISPR subtypes co-exist in 
an organism, they process their own crRNAs (Goldberg et al. 2014; Jackson & 
Wiedenheft 2015). The crRNA biogenesis stage is not conserved, and there are 
significant differences between type I, II and III. In the type I system, after a CRISPR 
locus is transcribed, the repeats form stable stem loops that are recognized and cleaved by 
a Cas6 family endoribonuclease (Hale et al. 2014). The products of this endoribonuclease 
reaction are 61 nucleotide long crRNAs that contain a unique spacer flanked by partial 
repeat segments. After processing, Cas6 remains bound to the crRNA and other type I 
Cas proteins bind to it forming a large multi-protein complex (Tamulaitis et al. 2014).  
The type I complex is known as the CRISPR-associated complex for antiviral defense 
(Cascade). In the type II system, a trans-encoded short RNA, termed trans-activation 
crRNA (tracrRNA), is required for crRNA processing (Samai et al. 2015). The tracrRNA 
has a 25-nucleotide segment that is almost always complementary to the repeat sequence 
in CRISPR loci, and the base pairing is required for the pre-cRNA and tracrRNA co-
processing. The processing is done by the endogenous RNase III nuclease.  The type III 
system utilizes a similar approach as the type I system. However, without the stem-loop 
feature in the repeats (Wang & Landick 1997), the endoribonuclease Cas6 binds to the 
first few bases from the 5’ end of the repeat and cleaves at 8 nucleotides upstream from 
the spacer (Makarova et al. 2011). Unique to type III systems, the 3’ end of the crRNA is 
further processed by an unknown mechanism at 6 nucleotide intervals and can generate 
mature crRNAs that contain variable repeat sequence on the 5’ end or just spacer 
sequence (Jung et al. 2015). Unlike the type I system, in the type III systems the crRNA 
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is handed off to a multi-protein effector complex containing subtype specific Cas proteins 
and Cas6 is not part of the complex (Westra et al. 2012; Sinkunas et al. 2013; Mulepati & 




 The interference stage of the CRISPR III-B subtype is the primary subject of my 
thesis, yet I will briefly delve into what is known about type I and II systems. After the 
assembly of the effector complex composed of crRNA and Cas protein(s), the foreign 
genetic element to which the crRNA is complementary can be recognized and degraded. 
The Cas proteins catalyze the destruction of invader sequences through different 
mechanisms. 
 
In the type I system, Cascade acts as a surveillance complex that will bind to 
protospacers to which its crRNA is complementary. Upon binding to a target protospacer, 
Cascade melts the double stranded target DNA and forms an R-loop with the 
complementary strand bound to the crRNA and the non-complementary strand is exposed 
(Hatoum-Aslan et al. 2014). This is believed to be a signal for Cas3 recruitment, which 
has Mg2+-dependent ssDNA cleavage activity and an ATP-dependent helicase domain, to 
degrade the protospacer containing foreign DNA (Hatoum-Aslan et al. 2014; Ramia, 
Tang, et al. 2014b; Samai et al. 2015). Cascade binding is ATP-independent and is 
proposed to nucleate at the 5’ end of the protospacer, where the seed sequence is, and 
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Watson-Crick base-pairing proceeds to the 3’ end (Staals et al. 2013). Binding is 
dependent on PAM, and in the silencing stage PAM is the determining factor in self-vs-
foreign targeting. CRISPR loci do not contain PAM sequences.  
 
In the type II system Cas9, with its tracrRNA and crRNA, binds to protospacers 
complementary to the crRNA. Binding to the PAM is the first step in target interference 
for the type II system (Garrett et al. 2015; Hale et al. 2012). This 3-5 base pair sequence 
serves as an initial screen of the invasive DNA sequence, if a match is found subsequent 
base pairing to the crRNA ensues in a manner similar to Cascade. Cas9 contains two 
nuclease active sites, the HNH domain and the RuvC-like domain, that allow it to cleave 
dsDNA directly. The complementary strand of the target DNA is cleaved by HNH 
nuclease domain while the non-complementary strand is cleaved by RuvC-like domain 
(Deng et al. 2013). 
 
In the type III system, multi-protein effector complexes target both DNA and 
RNA for degradation. Discrimination between self and non-self doesn’t occur through a 
PAM sequence like in the type I and II systems, instead a 5’ tag derived from the 
CRISPR repeat sequences on the crRNA biases foreign nucleic acid, with 
complementarity to the 5’ tag indicating self.  The type III systems bind and cleave 
single-stranded (ss) RNA (Samai et al. 2015), and transcriptionally active DNA (Peränen 
et al. 1996). The Type III systems can be further classified into subtypes and the Type III-
A and Type III-B subtypes are the best characterized. Both subtypes contain a Cas10 
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family protein, Cmr2 in Type III-B and Csm1 in Type III-A systems (Huang & Szostak 
1996). The III-A subtype has been shown to cleave ssRNA complementary to the crRNA 
at 6 nucleotide intervals by the Csm3 protein (Staals et al. 2014; Samai et al. 2015; 
Tamulaitis et al. 2014), but they have also been demonstrated to cleave DNA in a 
transcription-coupled manner. The III-B complex has also been demonstrated to cleave 
ssRNA at 6 nucleotide intervals by the Cmr4 protein (Benda et al. 2014; Ramia, Spilman, 
et al. 2014a).  In vivo genetic experiments have implicated the III-B complex in targeting 
transcriptionally active DNA, but the mechanism of this activity and the identity of the 

















Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and their 
associated (Cas) proteins form the basis of an inheritable and adaptable RNA-guided 
immune system in prokaryotes. For a recent review see (van der Oost et al. 2014). 
CRISPR loci are composed of repeat sequences separated by variable spacer sequences 
that are derived from foreign genetic elements (Bolotin et al. 2005; Mojica et al. 2005; 
Pourcel et al. 2005; Barrangou et al. 2007). Transcripts from CRISPR loci are processed 
to generate short CRISPR RNAs (crRNA) (Brouns et al. 2008; Carte et al. 2008; 
Deltcheva et al. 2011). The crRNA are then incorporated into effector complexes that 
identify and destroy invading nucleic acid that is complementary to the guide region of 
the crRNA (Brouns et al. 2008; Hale et al. 2009; Jinek et al. 2012; Gasiunas et al. 2012).  
 
CRISPR-Cas systems are organized into three types (Type I, II and III) and at 
least ten subtypes (Makarova et al. 2011). Each type has a distinct mechanism for 
processing CRISPR transcripts and for target destruction (Makarova et al. 2011)  and are 
distinguished by a signature protein, Cas3 in Type I, Cas9 in Type II and Cas10 in Type 
III. The effector complexes in Type I systems recognize their DNA targets and then 
recruit the Cas3 protein to degrade the invading DNA using its Histidine-Aspartate (HD) 
nuclease domain (Brouns et al. 2008; Westra et al. 2012; Mulepati & Bailey 2013; 
Sinkunas et al. 2013). Type II systems also target DNA but recognition and cleavage are 
mediated by the same effector complex, Cas9 (Jinek et al. 2012; Gasiunas et al. 2012). 
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The Type III systems bind and cleave single-stranded (ss) RNA (Hale et al. 2009; Zhang 
et al. 2012; Zebec et al. 2014; Staals et al. 2013; Staals et al. 2014; Tamulaitis et al. 2014; 
Samai et al. 2015; Hale et al. 2012) and transcriptionally active DNA (Goldberg et al. 
2014; Samai et al. 2015; Deng et al. 2013). The Type III systems can be further classified 
into Type III-A and Type III-B subtypes. Both subtypes contain a Cas10 family protein, 
Cmr2 in Type III-B and Csm1 in Type III-A systems (Makarova et al. 2011). Despite 
mechanistic differences, the Type I and Type III effector complexes share similar 
structures and likely evolved from a common ancestor (Jackson & Wiedenheft 2015). 
 
The Cmr complexes from the Type III-B systems of Pyrococcus furiosus, 
Thermus thermophilus and Sulfolobus solfataricus have all been characterized in vitro 
(Hale et al. 2009; Staals et al. 2013; Zhang et al. 2012). The Cmr effector complex 
consists of six proteins (Cmr1-6) and a crRNA. The crRNA is comprised of eight 
nucleotides of repeat sequence at its 5’ end (the 5’ handle) and typically 30-40 
nucleotides of invader-derived guide sequence at its 3’ end (Carte et al. 2008; Hale et al. 
2009; Staals et al. 2013). Multiple Cmr4 and Cmr5 subunits form a helical filament 
around the crRNA, which is capped at its 5’ end by Cmr2 and Cmr3 and at its 3’ end by 
Cmr6 and Cmr1 (Spilman et al. 2013; Staals et al. 2013; Taylor et al. 2015; Benda et al. 
2014; Osawa et al. 2015). Cmr4 serves as a catalytic subunit (Benda et al. 2014; Ramia, 
Spilman, et al. 2014a; Zhu & Ye 2015) cleaving paired ssRNA targets at regular 6 nt 
intervals (Hale et al. 2014; Staals et al. 2013). Cmr2 contains a predicted HD nuclease 
domain (Makarova et al. 2011), although this domain is dispensable for RNA target 
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cleavage by the Cmr complex (Cocozaki et al. 2012; Staals et al. 2014). The Csm 
complexes from the Type III-A systems have also been characterized in vitro. They have 
a similar structure to the Cmr complex (Staals et al. 2014; Rouillon et al. 2013) and 
likewise cleave complementary RNA at multiple sites (Samai et al. 2015; Staals et al. 
2014; Tamulaitis et al. 2014) but have also been shown to cleave DNA in a transcription-
coupled manner (Samai et al. 2015). 
 
In cells, genetic experiments have implicated the Cmr complex in targeting 
transcriptionally active DNA (Deng et al. 2013) but the mechanism of this activity and 
the identity of the DNA nuclease active site are unknown. We therefore undertook a 
















Figure 1.1 An overview of the viral life cycle and bacterial defense strategies. (A) The 
life cycle stages of a lytic virus. (B) Bacterial strategies to combat different stages of the 
viral life cycle. For simplicity, the outer membrane (gram-negative bacteria) and cell wall 





Figure 1.2 Representative CRISPR loci in a Prokaryotic Chromosome. The repeat 
sequences are shown in black, the spacers are colored and the cas genes are red. The 
spacers are numbered from newest (Spacer1) to oldest (Spacer3) integrated sequence. The 








Figure 1.4 Type I, II, and III CRISPR systems (Makarova et al. 2011). The signature 
proteins of the type I, II, and III systems are Cas3, Cas9, and Cas10, respectively. The 





Figure 1.5 The CRISPR immune system has three distinct stages. First, spacers 
complementary to the foreign protospacer are incorporated into the host genome. Second, 
subsequent attacks elicit transcription at CRISPR loci and the generation of CRISPR 
RNA through processing by Cas proteins. Third, CRISPR RNA is loaded onto Cas 


































Reconstitution of the Cmr complex from Thermotoga maritima 
 
The genome of Thermotoga maritima MSB8 contains three Cas modules (one 
each of types I-B, III-A and III-B) and eight CRISPR loci (Figure 2.1). Each CRISPR 
loci contains the same, or very similar, repeat sequence, suggesting that the three Cas 
modules can likely use crRNA processed from any of the CRISPR loci. The Type III-B 
module encodes six proteins (Cmr1-6). To determine if these six proteins can assemble 
into a Cmr complex we cloned, expressed and purified each Thermotoga maritima Cmr 
protein in an Escherichia coli expression system (Figure 2.2A). The recombinant proteins 
were mixed and the mixture purified over a nickel column (Cmr6 was N-terminally hexa-
histidine tagged, all of the other proteins were untagged) in either the presence or absence 
of a synthetic crRNA8.3 (which corresponds to the third crRNA encoded by CRISPR 
locus 8). In the absence of crRNA all but one of the Cmr proteins, Cmr1, purified as a 
complex, whereas in the presence of crRNA, all six Cmr proteins purified as a complex 
(Figure 2.2B). Weak association between Cmr1 and the Cmr complex has been noted in 
both T. thermophilus (Staals et al. 2013)and P. furiosus (Benda et al. 2014). 
 
We next asked if the organization of the Thermotoga maritima Cmr complex is 
similar to Cmr complexes from other organisms. To test this, we performed a series of 
pull-down experiments with combinations of Thermotoga maritima Cmr proteins. The 
results of these experiments are presented in Figure 2.3. The interactions between 
subunits observed in the Thermotoga maritima Cmr complex agrees with the interactions 
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observed between subunits of other Cmr complexes by electron microscopy, cross-
linking and X-ray crystallography (Spilman et al. 2013; Staals et al. 2013; Taylor et al. 
2015; Benda et al. 2014; Osawa et al. 2015), suggesting that the Thermotoga maritima 


















Materials and methods 
 
Purification of recombinant Cmr proteins 
 
The genes encoding Cmr1-6 were individually PCR amplified from Tma genomic 
DNA and cloned into pET derived vectors. The vectors, pHAT4 and pHAT2, contain an 
amino-terminal hexahistidine tag that is cleavable or not cleavable by tobacco etch virus 
protease (TEV), respectively. The vectors were transformed into T7Express cells (New 
England BioLabs) and grown to an OD600 of 0.3 in Luria-Bertani Medium, followed by 
induction with 0.2mM isopropyl-β-D-thiogalactopyranoside (IPTG) and overnight 
expression at room temperature. The cells were pelleted at 4,500 rpm, resuspended in 
lysis buffer (1 M KCl, 20 mM Tris-HCl at pH 8.0, 10 mM Imidazole and 1 mM tris(2-
carboxyethyl)phosphine (TCEP)) and disrupted using a French Press. The resulting 
sample was centrifuged at 18,000 rpm for 45 minutes at 4°C. The histidine tagged Cmr 
proteins were isolated from the supernatant using a 5mL IMAC column (Bio-Rad) 
charged with nickel sulfate and equilibrated with lysis buffer. After washing with at least 
100mL lysis buffer, the proteins were eluted with 250mM Imidazole containing lysis 
buffer and injected onto a HiLoad 26/60 S200 size exclusion column (GE Healthcare) 
equilibrated with gel filtration buffer (350 mM KCl, 20 mM Tris-HCl at pH 8.0 and 1 
mM TCEP). The above steps were carried out with Cmr proteins cloned into the pHAT2 
vector. When cloned into the pHAT4 vector histidine tag removal was accomplished by 
elution off of IMAC as above, followed by buffer exchange with a HiPrep 26/10 
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desalting column (GE Healthcare) equilibrated with gel filtration buffer and incubation 
with TEV protease overnight at 4°C. The sample is re-applied to the IMAC column to 
remove the cleaved histidine tag and histidine tag containing TEV protease, the flow-
through is collected and injected onto a HiLoad 26/60 S200 size exclusion column 
equilibrated with gel filtration buffer. Fractions collected from the size exclusion column 
were analyzed by SDS-PAGE. The Cmr2 and Cmr4 mutants were created by PCR-based 
mutagenesis. The expression vector was amplified using phosphorylated mutagenic 
primers followed by self-ligation. All mutant proteins were expressed and purified using 
the same protocol as the respective wild-type protein. 
 
Pull-down assay  
 
Purified Cmr proteins that were tagged (bait) and untagged (prey) were incubated 
in 100µL binding buffer (100 mM KCl, 20 mM Tris-HCl at pH8.0, 10 mM Imidazole, 1 
mM TCEP) for 30 min at 37°C. 20µL of nickel sulfate charged IMAC resin (BioRad) 
equilibrated in binding buffer is added to the Cmr protein sample and incubated for 1 hr 
at 4°C on a rotating plate. The resin was washed three times with 0.5 mL binding buffer 
and further incubated with elution buffer (binding buffer containing 250 mM Imidazole) 
for 30 min at 4°C. Proteins eluted from the beads were analyzed on 4-20% Mini-Protean 








Figure 2.1 Schematic representation of the CRISPR arrays and cas genes in the genome 
of Thermotoga maritima MSB8. CRISPR arrays are grey, Type III-B genes are red, Type 
I-B are green and Type III-A are blue. Genes involved in Integration and Processing are 
orange and purple, respectively. The repeat sequence of each array is shown, with the 5’ 










Figure 2.2 Assembly of the Thermotoga maritima Cmr complex. SDS-polyacrylamide 
gels, stained with Coomassie blue, of individually purified Cmr subunits (A) and  













Figure 2.3 Pairwise interactions between Cmr subunits.  (A-F) Pairwise pull-downs with 
each of the Cmr subunits as untagged prey against N-terminal His-tagged bait. (G) 






Figure 2.4 Interactions within the Cmr complex.  (A-E) Pull-down experiments using the 
binary complexes identified in Figure 2.3 as untagged prey against N-terminal His-tagged 









































The Thermotoga maritima Cmr complex cleaves ssRNA 
 
In vitro the Cmr complexes from P. furiosus, S. solfataricus and T. thermophilus 
cleave ssRNA that is complementary to the crRNA (Hale et al. 2009; Zhang et al. 2012; 
Staals et al. 2013). To determine the substrate specificity of the Thermotoga maritima 
Cmr complex, we incubated the complex with crRNA8.3 and a selection of nucleic acid 
targets that were radiolabeled at their 5’ ends (5’-labeled). Reactions were incubated for 
10 minutes at 80°C, the optimal growth temperature of Thermotoga maritima (Huber et 
al. 1986), and the products were analyzed by denaturing PAGE followed by 
autoradiography. Neither non-complementary ssRNA, complementary ssDNA nor 
double-stranded (ds) RNA were cleaved (Figure 3.1A). Only complementary ssRNA (the 
ssRNA8.3 target) was cleaved, with the cleavage site located 14 nucleotides from the 3’ 
end of the paired crRNA (Figure 3.1). Cleavage appeared to be sequence-independent as 
a ssRNA target complementary to a crRNA with a different sequence (crRNA8.4 and 
ssRNA8.4) also resulted in the same 14-nt cleavage product (Figure 3.1A), in agreement 
with results from the P. furiosus Cmr complex (Hale et al. 2012), and like other Type III 
complexes was dependent on the presence of magnesium or manganese ions (Figure 3.2) 
(Hale et al. 2009; Staals et al. 2014; Staals et al. 2013; Zhang et al. 2012; Samai et al. 
2015; Tamulaitis et al. 2014). Further characterization of the cleavage activity revealed 
that the Cmr complex cleaves the target RNA on the 5’ side of the phosphodiester bond 
like the P. furiosus Cmr complex (Hale et al. 2009). The cleavage product generated by 
the complex is not a substrate for polyadenylation (Figure 3.3), indicating the presence of 
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a 3’ phosphate (or 2’, 3’ cyclic phosphate) end. Target cleavage also required that the 5’ 
handle of the crRNA was intact and had the correct repeat-derived sequence (Figure 
3.1B). 
 
Other Cmr complexes can cleave their RNA targets at up to five sites that are 
separated by 6 nt intervals (Staals et al. 2013; Hale et al. 2014). To determine the 
frequency and spacing of target cleavage by the Thermotoga maritima Cmr complex, we 
monitored cleavage of a 5’-labeled ssRNA8.3 target as a function of time. The results 
show the target was cleaved at four sites (sites 1, 2, 3 and 4), each separated by 6 nt, 
producing 32, 26, 20 and 14-nt products (Figure 3.1C). Cleavage at site 1 is minimal 
compared to the other three sites, which was also observed with the P. furiosus and T. 
thermophilus Cmr complexes (Staals et al. 2013; Hale et al. 2014). The appearance and 
disappearance of the cleavage products over time suggest that the target is cleaved 
sequentially, starting predominantly at site 2 and then proceeding to site 3 then to site 4 
(Figure 3.1E). After ~5 minutes the target is almost completely cleaved to a single 
prominent 14-nt product, which is much faster than observed with P. furiosus and T. 
thermophilus Cmr complexes (Hale et al. 2009; Staals et al. 2013). To confirm cleavage 
is sequential we repeated this experiment but used a 3’-labeled target. In this experiment 
we observed a single prominent 12-nt product (Figure 3.1D), corresponding to cleavage 
at site 2 (note that the 3’-end labeling reaction added one additional nucleotide to the 3’-
end of the RNA target), suggesting that cleavage primarily begins at site 2. 
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To gain further insights into the determinants for RNA cleavage we tested activity 
on RNA targets that would result in base-pairing-disrupting mismatches when paired 
with crRNA8.3. RNA targets that result in mismatches at position 20 and/or position 21, 
which flank the scissile phosphate at site 3, do not inhibit cleavage of the target at any 
site. In fact, cleavage of these mismatched targets appears to be enhanced relative to the 
fully complementary target, as with these targets we observe an increased proportion of 
the site 4 product relative to the fully complementary target (experiments 1-4 in Figure 
3.4A). Thus, perfect complementarity is not required at site 3, suggesting that RNA 
cleavage by the Cmr complex, like the related Csm complexes (Staals et al. 2014; 
Tamulaitis et al. 2014), is not strictly dependent on complete complementarity between 
the crRNA and RNA target. 
 
It has been shown that the 2’-hydroxyl group adjacent to the scissile phosphate is 
crucial for the RNA cleavage activity of a chimeric Cmr complex reconstituted from 
Archaeoglobus fulgidus Cmr1-3 and P. furiosus Cmr4-6 (Osawa et al. 2015). We 
confirmed the importance of this hydroxyl group to cleavage by the Thermotoga 
maritima Cmr complex. An ssRNA8.3 target containing a 2’-deoxyribose at position 20 
was not cleaved at site 3 (experiment 5 Figure 3.4A) but in a control experiment a target 
with a 2’-deoxyribose at position 21 was cleaved at site 3 (experiment 6 in Figure 3.4A). 
Furthermore, when any of the four cleavage sites were blocked with a 2’-deoxyribose we 
observed no cleavage at that site (experiments 7 through 11 in Figure 3.4B). A modified 
ssRNA8.3 target (ssRNA8.3*) that contained 2’-deoxyribose base substitutions at each of 
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the four cut sites (positions 14, 20, 26 and 32) was not cleaved by the Cmr complex 
(experiment 12 in Figure 3.4B). To confirm that the 2’-deoxyribose modifications in 
ssRNA8.3* do not interfere with binding to the Cmr complex we performed competition 
experiments. Thus, we monitored cleavage of the 5’-labeled ssRNA8.3 target using either 
unlabeled ssRNA8.3* as a specific competitor or ssRNA8.4 as an unspecific competitor. 
Only the unlabeled crRNA8.3* inhibited cleavage of the target (lane 3 in Figure 3.4C) 















Materials and methods 
 
Preparation of labeled oligonucleotides 
 
RNA oligonucleotides were purchased from Sigma Aldrich (Table 1.1). They 
were 5’ radiolabeled with T4 polynucleotide kinase (New England BioLabs) and γ-32P 
ATP (Perkin Elmer) in 1x T4 polynucleotide kinase buffer at 37°C for 30 min. The 
substrates were resolved on a denaturing polyacrylamide gel, visualized by 
autoradiography, excised from the gel and placed in a 0.5mL solution of 0.3M sodium 
acetate overnight at 4°C followed by ethanol precipitation and resuspension in RNA 
Storage Solution (Ambion) for RNA. To generate dsRNA targets, labeled oligonucleotide 
with twice molar excess of complementary unlabeled oligonucleotide was incubated at 
95°C for 10 min, followed by slow cooling to room temperature. Non-denaturing PAGE 
confirmed complete annealing. 
 
Radiolabeling of the 3’ end of ssRNA was performed as previously described 
(Huang & Szostak 1996). Briefly, ssRNA was annealed to a short ssDNA 
oligonucleotide, complementary to the 3’-end of ssRNA, generating a TG overhang. The 
duplex was then incubated with 3’-5’ exonuclease deficient Klenow Fragment (New 
England BioLabs) and α-32P dATP (Perkin Elmer) in 1x Buffer 2 (New England Biolabs) 
at 37°C for 2 hr. Following the reaction the ssDNA was removed by denaturing PAGE.  
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RNA cleavage assays 
 
Cmr2-6 was formed by pull-down (see Chapter 2 Materials and Methods). Unless 
otherwise indicated, 250 nM Cmr2-6, 250 nM Cmr1, and 100 nM crRNA were incubated 
at 80°C for 30 min, in reaction buffer (100 mM KCl, 20 mM HEPES at pH 7, 1 mM 
MnCl2, 0.5 mM ATP and 1 mM TCEP). The reaction (80°C) was initiated by addition of 
1 nM (unless otherwise indicated) radiolabeled target. The reaction was stopped at 10 
min or the indicated time point with the addition of quencher dye (90% formamide, 2.5% 
glycerol, 0.01% SDS, 0.01% bromophenol blue, 0.01% xylene cyanol and 1mM EDTA) 
and heated at 95°C for 10 min. Radiolabeled RNA ladders were generated with RNase T1 
(New England Biolabs) or alkaline hydrolysis buffer (50 mM sodium carbonate pH 9.2 
and 1 mM EDTA). The samples are then run on 20% polyacrylamide denaturing gels and 
visualized by phosphorimaging.  
  
 For analysis of the chemical ends of the cleavage products, cleavage reactions 
were performed using 5’-end labeled target as described above. The resulting RNA 
products were isolated by PCI extraction and ethanol precipitation, and subject to 
polyadenylation by incubation with 5 U E. coli polyA polymerase (NEB) for 15 min at 
37oC as described by the manufacturer. The reaction was stopped by PCI extraction, 
followed by ethanol precipitation. The resulting products were analyzed on 20% 







Figure 3.1. The Thermotoga maritima Cmr complex cleaves ssRNA. (A) The indicated 
5’-labeled substrates were incubated with (+) or without (-) the Cmr complex and the 
products resolved on a denaturing polyacrylamide gel. (B) Requirement of the crRNA 
and determinant of its repeat derived 5’-handle. (C, D) 5’- and 3’-labeled ssRNA8.3 
targets were incubated with the Cmr complex for the indicated times and resolved on 
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denaturing polyacrylamide gels. In all panels, T1 and OH denote the T1 and hydroxide 
ladders, respectively. (E) Schematic depicting the cleavage sites on the ssRNA8.3 target 
in relation to crRNA8.3. The sizes of the cleavage products are indicated. Note that the 


















Figure 3.2 RNA cleavage by the Cmr complex is metal dependent. ssRNA8.3 target was 
incubated in the presence of the Cmr complex/crRNA8.3 with MgCl2, MnCl2, without 






Figure 3.3 5’ end-labeled target RNA and Cmr complex cleavage products were subject 
to polyadenylation by E. coli polyA polymerase (+) or no treatment (–). The position of 
the target RNA and polyadenylated target RNA are indicated. Also indicated is the 
location of the cleavage product. No polyadenylation of the cleavage products was 






Figure 3.4 Determinants for RNA cleavage by the Thermotoga maritima Cmr Complex. 
Modified ssRNA8.3 targets were incubated with the Cmr complex and the products 
resolved on a denaturing polyacrylamide gel. (A) ssRNA targets were modified to 
contain either mismatches or 2’- deoxyribonucleotides at the indicated positions. A 
schematic of the modified targets is shown on the right. (B) Modified ssRNA targets with 
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2’-deoxyribonucleotide blocks at the indicated cleavage site(s). A schematic of the 
modified targets is shown on the right. (C) Completion experiments where the Cmr 
complex was incubated with the ssRNA8.3 target and either no competitor, a specific 




















Table 3.1 Sequence of RNA oligonucleotides used in assays  





guide crRNA8.3 (no psi-tag) 
CCGUCCCUUCUUUCCUGUCUUUUUGC
CUCCUUUAAGU 





























































DNA cleavage by the Cmr complex   
 
Genetic experiments implicate the Cmr complex in targeting transcriptionally 
active plasmid DNA in cells (Deng et al. 2013). Yet, Cmr complexes have only been 
observed to cleave RNA and not DNA in vitro (Figure 3.1A) (Hale et al. 2009; Staals et 
al. 2013; Zhang et al. 2012) and in vivo (Hale et al. 2012; Zebec et al. 2014).We reasoned 
that these differing observations could be reconciled if the DNA nuclease activity of the 
Cmr complex required the presence of a ssRNA transcript. To test this we incubated the 
Thermotoga maritima Cmr complex with crRNA8.3, an ssRNA8.3 target (a mimicking a 
transcript) and one of either of two different ssDNA substrates (substrate A and B), 
which were 5’-labeled (Figure 4.1A). The ssDNA substrates we selected were chosen at 
random and are not related at all in sequence to the crRNA or target RNA. We initially 
screened ssDNA as a potential substrate because Csm1 (which like Cmr2 is a Cas10 
family protein) has ssDNA nuclease activity (Jung et al. 2015) and is the only subunit of 
a Type III effector complex with known DNA nuclease activity. The Cmr complex cut 
the DNA substrate weakly at multiple sites only when it and ssRNA8.3 target were added 
to the reaction at the same time (lanes 4 and 11 in Figure 4.1B). No cleavage was 
observed if the Cmr complex was pre-incubated with the ssRNA8.3 target for 10 minutes 
before addition of the ssDNA (lanes 3 and 10 in Figure 4.1B). This suggested cleavage of 
the ssRNA target may inhibit cleavage of the ssDNA substrate. No DNA cleavage was 
observed in the absence of the Cmr complex, in the absence of the complementary 
ssRNA8.3 target (Figure 4.1B) or with an ssRNA target non-complementary to 
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crRNA8.3 (lanes 7 and 14 in Figure 4.1B). Cleavage was dependent on the presence of 
manganese ions but not magnesium ions (Figure 4.2) and was specific to ssDNA as no 
cleavage of either ssRNA or dsDNA (Figure 4.1A) was observed under the same 
reactions conditions (lanes 15-18 in Figure 4.1B).  
 
To further investigate the effects of RNA cleavage on the DNA cleavage activity 
of the Cmr complex, we monitored DNA cleavage under two regimes where the ssRNA 
target is not cut. Firstly, we monitored DNA cleavage using the non-cleavable 
ssRNA8.3* as the RNA target. Secondly, we monitored DNA cleavage using a Cmr 
complex that was reconstituted with Cmr4 harboring a D26A mutation (Benda et al. 
2014; Ramia, Spilman, et al. 2014a; Zhu & Ye 2015). This variant of the Thermotoga 
maritima Cmr complex binds to (lane 3 in Figure 4.3) but is unable to cleave a 
complementary RNA target (lane 4 in Figure 4.4B). Under both of these regimes 
cleavage of the ssDNA was greatly enhanced (lanes 5-6 and lanes 12-13 in Figure 4.1B) 
suggesting that cleavage of the RNA target inhibits cleavage of ssDNA by the Cmr 
complex.  
 
RNA target binding licenses ssDNA cleavage 
 
Our results suggest that RNA target binding licenses ssDNA cleavage by the Cmr 
complex. To gain additional insight into this licensing we investigated RNA cleavage 
more closely. First, we wished to determine if the RNA products dissociate from the Cmr 
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complex following cleavage or if they remain bound. Thus, Cmr complex pre-
equilibrated with an equimolar amount of crRNA8.3 was incubated with either 
equimolar, or 2- or 4-fold excess of the ssRNA8.3 target. Cleavage was monitored over 
time by denaturing PAGE followed by autoradiography. If RNA products do not 
dissociate from the complex following cleavage then in reactions with target in excess the 
amount of target cleaved should equal the amount of Cmr complex in the reaction. 
However, at all ratios of Cmr complex to target tested approximately 100% of the 
ssRNA8.3 target was cleaved (Figure 4.5A), indicating that the RNA products dissociate 
from the complex following cleavage. In a second set of experiments, the Cmr complex, 
pre-equilibrated with crRNA8.3 (1:1 stoichiometry) was incubated with 100 nM of target 
ssRNA8.3 and 1 nM of ssDNA substrate A (5’-radiolabeled). Cleavage of the DNA was 
monitored over time until the accumulation of product had plateaued (Figure 4.5B). Note 
that under these conditions (100nM of ssRNA8.3 target), the DNA cleavage activity of 
the Cmr complex is more robust than in previous experiments, where the concentration of 
the ssRNA8.3 target was much lower (1nM). Once the accumulation of product had 
plateaued either fresh complementary (ssRNA8.3) or in a control experiment non-
complementary (ssRNA8.4) RNA targets were added to the reactions and we continued 
to monitor DNA cleavage (Figure 4.5B). Addition of fresh complementary ssRNA8.3 re-
initiated cleavage of the ssDNA, whereas the non-complementary ssRNA8.4 had no 
effect, suggesting that the RNA products had dissociated from the complex.  If the RNA 
products aren’t released after cleavage then addition of fresh target should have no effect. 
Together these data indicate that the presence of an intact ssRNA target complementary 
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to the crRNA activates a ssDNA nuclease activity in the Cmr complex, and that cleavage 
of the ssRNA target and dissociation of the resulting fragments then prevent DNA 
cleavage. 
 In Type III-A systems base-pairing between the 5’-handle of the crRNA and the 
3’-flanking sequence of the RNA target has been shown to have no effect on RNA target 
cleavage but inhibits cleavage of the DNA (Samai et al. 2015; Marraffini & Sontheimer 
2010b). We tested the effects of complementarity to the 5’-handle on RNA and DNA 
cleavage by the Thermotoga maritima Cmr complex and found that the RNA was 
cleaved, albeit to a lesser extent (lane 5 in Figure 4.4A), and that cleavage of DNA was 
almost undetectable (lane 5 in Figure 4.4B). Thus, activation of DNA cleavage by the 
Cmr complex also requires a lack of complementarity between the RNA target and the 
crRNA 5’-handle. 
 
Sequence specificity for the ssDNA target  
 
The Cmr complex was able to cleave two ssDNA substrates with distinct 
sequences suggesting that the ssDNA nuclease activity of the Cmr complex is not 
sequence specific. However, cleavage of each substrate produced a distinct band pattern 
(Figure 4.1B) indicating some sequence preference at the sites of cleavage. To investigate 
this further we mapped the length of the cleavage products for the two different ssDNA 
substrates (Figure 4.1A). This mapping revealed the Cmr complex cleaved the DNA after 
every thymidine and not after any other nucleotide. Thymidine specificity was further 
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verified using a series of DNA substrates (derived from substrate A) where cleavage was 
blocked at the sites where thymidines were replaced with adenosine (Figure 4.6A). A 
ssDNA substrate completely lacking thymidine was not cleaved by the Cmr complex 
(Figure 4.6A). 
 
In addition to the observed thymidine specificity, cleavage between a thymidine 
and a cytidine appeared to be less efficient than cleavage between a thymidine and any 
other nucleotide (see the 17-nt product of substrate A and the 22 nt product of substrate B 
in Figure 4.1B). Substrate A contains a single thymidine-cytidine dinucleotide sequence, 
located at positions 17-18 (Figure 4.2C). We mutated this cytidine (C18) to each of the 
other three nucleotides and monitored cleavage of the modified DNA substrate. Cleavage 
at position 17 of these modified substrates was more robust than in substrate A (Figure 
4.6B). Thus, confirming that cleavage between a thymidine and a cytidine is less efficient 
than cleavage between thymidine and any other nucleotide. 
 
Cleavage of ssDNA in the context of dsDNA 
 
To determine if the Thermotoga maritima Cmr complex can cleave ssDNA in the 
context of dsDNA we generated a series of dsDNA substrates that contained mismatched 
“bubble” regions. The “bubble” regions ranged in size from 2-10 nt and consisted of a 
poly-thymidine sequence on one strand (the T-strand) and a poly-cytidine sequence on 
the opposite strand (the C-strand) (Figure 4.6C). The double-stranded regions of these 
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substrates were designed such that they did not melt at the reaction temperature, 80°C. 
The “bubble” substrates (labeled at the 5’-end of their T-strands) were incubated with the 
Thermotoga maritima Cmr complex, crRNA8.3 and an ssRNA8.3 target and then 
analyzed by denaturing PAGE and autoradiography. Each of the substrates was cleaved 
multiple times within the bubble region (Figure 4.6C) suggesting the Cmr complex can 
cleave ssDNA regions as short as 2-nt in the context of dsDNA. 
 
Mutations in the HD domain of Cmr2 abolish ssDNA cleavage 
 
The ssDNA nuclease activity of isolated Csm1 has been attributed to its HD 
domain (Jung et al. 2015).We reasoned that the HD domain of Cmr2 might be 
responsible for the observed ssDNA cleavage activity of the Cmr complex. To test this 
prediction, we made a mutant Cmr2 in which two highly conserved residues in the HD 
motif (His32 and Asp33) were substituted with alanine. The mutant Cmr2 (the HD-AA 
mutant) was then assembled into the Cmr complex and incubated with crRNA8.3 and 
either a 5’-labeled ssRNA8.3 target or a 5’-labeled ssDNA and an unlabeled ssRNA8.3 
target. After a 10 minute incubation at 80°C, the HD-AA mutant complex did not cleave 
the ssDNA (lane 3 in Figure 4.7), but did cleave the ssRNA8.3 target to a 14 nt product 
(Figure 4.7). These observations suggest that the conserved HD-motif found in Cmr2 is 
critical for the ssDNA endonuclease activity of the Cmr complex. 
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In the Type III-A system of Staphylococcus epidermidis the GGDD motif in the 
palm domain of Csm1 is required for DNA cleavage and not the HD domain (Hatoum-
Aslan et al. 2014; Samai et al. 2015; Ramia, Tang, et al. 2014b). To test if the GGDD 
motif has a role in DNA cleavage by the Thermotoga maritima Cmr complex we made a 
mutant Cmr2 in which the two highly conserved aspartate residues in the GGDD motif 
were substituted with alanine. The mutant Cmr2 (the GGDD-GGAA mutant) was then 
assembled into the Cmr complex and its cleavage activities were accessed as before with 
the HD-AA mutant. The GGDD-GGAA mutant complex failed to cleave ssDNA (lane 4 
in Figure 4.7) but also failed to cleave the complementary ssRNA8.3 target (lane 8 in 
Figure 4.7). To further investigate why this mutant failed to cleave the RNA target, we 
used our electrophoretic mobility shift assay to access its specific binding to a 
complementary RNA target (lanes 5 and 10 in Figure 4.3). We found that the GGDD-
GGAA mutant complex did not bind a complementary RNA target. This suggests that 
mutation of the GGDD motif in Thermotoga maritima Cmr2 subunit results in a 
dysfunctional Cmr complex that cannot bind complementary RNA targets and thus 






Materials and methods 
	
Preparation of labeled oligonucleotides 
 
DNA oligonucleotides were purchased from Sigma Aldrich (Table 4.1). They 
were 5’ radiolabeled with T4 polynucleotide kinase (New England BioLabs) and γ-32P 
ATP (Perkin Elmer) in 1x T4 polynucleotide kinase buffer at 37°C for 30 min. The 
substrates were resolved on a denaturing polyacrylamide gel, visualized by 
autoradiography, excised from the gel and placed in a 0.5mL solution of 0.3M sodium 
acetate overnight at 4°C followed by ethanol precipitation and resuspension in RNA 
Storage Solution (Ambion) for RNA. To generate dsDNA targets, labeled oligonucleotide 
with twice molar excess of complementary unlabeled oligonucleotide was incubated at 
95°C for 10 min, followed by slow cooling to room temperature. Non-denaturing PAGE 
confirmed complete annealing. 
 
 
DNA cleavage assay 
 
Cmr2-6 was formed by pull-down (see Chapter 2 Materials and Methods). 250 
nM Cmr2-6, 250 nM Cmr1 and 100 nM crRNA were incubated at 80°C for 30 min, in 
reaction buffer (100 mM KCl, 20 mM HEPES at pH 7, 1 mM MnCl2, 0.5 mM ATP and 1 
mM TCEP). This complex was then incubated with both a target RNA (1nM, unless 
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otherwise indicated) and 5’-labeled ssDNA (1nM, unless otherwise indicated) substrate 
in reaction buffer for 10 min at 80°C. The reaction was stopped at 10 min or the indicated 
time point by performing a phenol-chloroform extraction. The resulting water soluble 
fraction is added to equal parts quencher dye (90% formamide, 2.5% glycerol, 0.01% 
SDS, 0.01% bromophenol blue, 0.01% xylene cyanol and 1 mM EDTA) and heated at 
95°C for 10 min. Radiolabeled DNA ladders were generated by purchasing 
oligonucleotides of defined sizes and 5’ labeling them as above. The samples are then run 
on polyacrylamide denaturing gels and visualized by phosphorimaging. 
 
Electrophoretic mobility shift assay 
 
1nM of 5’-labeled RNA target was incubated with 800nM Cmr complex (wild-
type and mutants complexes) loaded with 800nM crRNA8.3 for 1 hour at 4°C in reaction 
buffer. RNA cleavage is undetectable under these conditions. Following incubation 
bound RNA target was resolved from free target by electrophoresis through a 5% 














Figure 4.1 DNA cleavage by the Cmr complex. (A) 5’-labeled ssDNA substrates 
(substrates A and B), an ssRNA (whose sequence is equivalent to ssDNA substrate A) or 
a dsDNA (substrate A annealed to a complementary oligo) were incubated with the Cmr 
complex in the presence of ssRNA8.3 targets and then analyzed by denaturing PAGE. A 
“*” indicates the use of the non-cleavable ssRNA8.3* target, “8.4” indicates the use of 
the ssRNA8.4 target. M denotes the marker lane. (B) Schematic showing the mapping of 







Figure 4.2 DNA cleavage by the Cmr complex is metal dependent. ssDNA Substrate A is 
incubated in the presence of the Cmr complex with MgCl2, MnCl2, without metal, and 























Figure 4.4 Mutation of the D26A residue in Cmr4 eliminates ssRNA cleavage and 
complementarity by the target RNA to the crRNA at the 5’ handle diminishes ssDNA 
activity. (A) Cleavage of 5’ radiolabeled ssRNA8.3 and ssRNA8.3+3’ incubated with 
wild-type or Cmr4 D26A containing Cmr complexes. ssRNA8.3+3’ contains 8 nt on its 
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3’-end that are complementary to the 5’ handle of the crRNA. (B) 5’ radiolabeled ssDNA 
substrate A is mixed with the indicated Cmr complex containing either ssRNA8.3 or 




Figure 4.5 RNA turnover by the Cmr complex. (A) 5′ labeled ssRNA8.3 target was 
incubated with the Cmr complex in the presence of unlabeled crRNA8.3 at the indicated 
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concentrations, and cleavage was monitored over time. “T1” denotes the T1 lad- der, and 
“C” denotes a control lane containing only the labeled ssRNA8.3 target. (B) 5′ labeled 
ssDNA substrate A was incubated with the unlabeled ssRNA8.3, the Cmr complex, and 
crRNA8.3 for 30 min before either fresh ssRNA8.3 or ssRNA8.4 was added to the 
reaction (pulse), which was then monitored for a further 30 min. Samples were analyzed 
by denaturing PAGE. Below the gel panel is a quantification of the cleavage activity over 





with the Cmr complex and analyzed by denaturing PAGE. Below the gel is a schematic 






























Figure 4.7 Effects of mutations in Cmr2. 5′ labeled ssRNA8.3 target (right) or 5′ labeled 
ssDNA substrate A with unlabeled ssRNA8.3 target (left) was incubated with either wild-
type (WT) or mutant Cmr complexes (assembled with Cmr2 HD-AA or Cmr2 DD-AA) 
and then analyzed by denaturing PAGE. “L” denotes a DNA ladder, and “T1” denotes a 









Table 4.1 Sequence of DNA oligonucleotides used in assays  




  T20A CGGAGAACGTATGCGTTCGAACCACGACGG 
  T17A CGGAGAACGTATGCGTACGTACCACGACGG 
  T16A CGGAGAACGTATGCGATCGTACCACGACGG 
  T12A CGGAGAACGTAAGCGTTCGTACCACGACGG 
  T10A CGGAGAACGAATGCGTTCGTACCACGACGG 
  no T's CGGAGAACGAAAGCGAACGAACCACGACGG 
  C18 CGGAGAACGTATGCGTTCGTACCACGACGG 
  C18A CGGAGAACGTATGCGTTAGTACCACGACGG 
  C18T CGGAGAACGTATGCGTTTGTACCACGACGG 















































































The Cmr complex from the Type III-B CRISPR-Cas system is a crRNA 
programmed effector complex that cleaves complementary RNA in vitro (Hale et al. 
2009; Zhang et al. 2012; Staals et al. 2013) and in vivo (Hale et al. 2012; Zebec et al. 
2014). The Cmr complex also protects against plasmid transformation in vivo in a 
transcription dependent manner (Deng et al. 2013). All known CRISPR-Cas systems that 
protect against DNA invasion do so by degrading the invading DNA (Garneau et al. 
2010; Westra et al. 2012; Samai et al. 2015), suggesting that DNA targeting by the Cmr 
complex may also be mediated by DNA cleavage. Here we show the Cmr complex 
cleaves ssDNA in the presence of a complementary RNA target (Figure 4.1) and discuss 
the implications of this finding. 
 
We demonstrate that Cmr proteins from Thermotoga maritima assemble into a 
Cmr complex (Figure 2.3 and Figure 2.4) with the same subunit interactions as those 
observed for Cmr complexes from other species (Spilman et al. 2013; Staals et al. 2013; 
Taylor et al. 2015; Benda et al. 2014; Osawa et al. 2015). Thermotoga maritima Cmr 
complex specifically cleaves RNA targets that are complementary to crRNA. Cleavage 
occurs sequentially over four sites, separated by 6 nt intervals (Figure 3.1C-E), and is 
catalyzed by the Cmr4 subunit (lane 4 in Figure) (Benda et al. 2014; Ramia, Spilman, et 
al. 2014a; Zhu & Ye 2015). As observed previously with a chimeric Cmr complex 
(Osawa et al. 2015) we demonstrate that cleavage is dependent on the 2’ hydroxyl 
adjacent to the scissile phosphate (Figure 3.4). We also find that RNA cleavage by the 
Cmr complex can tolerate mismatches in the region of a cut site (Figure 3.4A). A 
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tolerance for mismatches was also observed with Csm complexes (Staals et al. 2014; 
Tamulaitis et al. 2014), suggesting that both Type III-A and Type III-B systems have 
flexibility in target specificity. 
 
The Type III CRISPR-Cas systems protect cells from invasion by DNA viruses 
and plasmids in a transcription-coupled manner (Deng et al. 2013; Goldberg et al. 2014; 
Samai et al. 2015). Here we show that a purified Cmr complex can cleave ssDNA after 
thymidine nucleotides but only in the presence of a complementary ssRNA target (Figure 
4.1). The S. solfataricus Cmr complex has been reported to cleave RNA targets at 
uridine-adenosine dinucleotides (Zhang et al. 2012), suggesting that sequence-specific 
cleavage of their substrates maybe a more general feature of Cmr complexes. RNA-
activated DNA cleavage by the Cmr complex provides a basis for the previously 
observed transcription-coupled DNA targeting. Binding but not cleavage of the ssRNA 
target was required to activate DNA cleavage (Figs. 3, 4, S5 and S6), consistent with 
immunity against plasmid transformation in the Type III-A system requiring DNA, but 
not RNA cleavage (Samai et al. 2015). Although the structural basis of DNA nuclease 
activation is unknown, it may involve the conformational rearrangements observed on 
complementary target binding by cryo-electron microscopy (Taylor et al. 2015). We 
mapped the active site for ssDNA cleavage to the HD domain of Cmr2 (Figure 6A). 
Transcription-coupled DNA cleavage may therefore target regions of ssDNA that are 
generated by transcription, likely at the displaced non-template strand (Figure 7) (Samai 
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et al. 2015; Jackson & Wiedenheft 2015). Accordingly, we observe cleavage of dsDNA 
that contains a mismatched “bubble” region as small as two nucleotides (Figure 4.6C). 
Several subunits of the Type I and Type III CRISPR-Cas complexes share distant 
phylogenetic relationships (Makarova et al. 2011; Makarova et al. 2015) and 
accumulating structural data suggests that these complexes may have evolved from a 
common ancestor, reviewed in (Jackson & Wiedenheft 2015). Our studies indicate that 
the HD domain of Cmr2 is the domain responsible for DNA cleavage in Type III-B 
systems. In Type I systems DNA is also cleaved by an HD domain, in the helicase-
nuclease Cas3, providing a further evolutionary link between the two systems. Indeed, 
the HD domains of Cmr2 and Cas3 both depend on transition metals and not magnesium 
for catalysis and both cleave ssDNA (Mulepati & Bailey 2011). S. thermophilus Cas3 has 
also been shown to preferentially cleave after thymidine nucleotides (Sinkunas et al. 
2013). 
 
The immunity against DNA invasion provided by the Type III CRISPR-Cas 
systems is dependent on COG1517 proteins (Makarova et al. 2012), Csm6 in Type III-A 
systems (Hatoum-Aslan et al. 2014) and Csx1 in Type III-B systems (Deng et al. 2013). 
Yet, none of these proteins stably associate with their respective effector complexes 
(Hale et al. 2009; Hatoum-Aslan et al. 2014) nor are they required for RNA cleavage by 
either complex (Figure 3.1) (Hale et al. 2009; Zhang et al. 2012; Staals et al. 2013; Staals 
et al. 2014; Tamulaitis et al. 2014; Samai et al. 2015). We also show cleavage of ssDNA 
by RNA-activated Cmr complex does not require the presence of Csx1 (Figure 4.1, 4.2 
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and 4.3). Likewise, transcription-coupled cleavage of DNA by the Csm complex does not 
require Csm6 (Samai et al. 2015). Thus, Csx1 and Csm6 do not appear to have a direct 
role in either RNA or DNA cleavage by the Type III effector complexes. Further 
biochemical studies are needed to understand the function of these proteins, although 
interestingly sequence analysis suggests this family of proteins may be nucleases 
(Makarova et al. 2012). 
 
Two models have been proposed for how a Type III effector complex could 
identify its DNA target using a crRNA. In the first model, crRNA pairs with the non-
template strand that has been exposed by a transcription bubble (Deng et al. 2013; 
Goldberg et al. 2014; Samai et al. 2015). In the second, crRNA pairs with the nascent 
transcript (Goldberg et al. 2014; Jackson & Wiedenheft 2015). We observe that pairing of 
a crRNA with an RNA target activates ssDNA cleavage by the Cmr complex and the 
sequence specificity of this nuclease activity has no dependence on the crRNA sequence. 
Also, the P. furiosus Cmr complex does not bind ssDNA that is complementary to the 
crRNA but does bind complementary ssRNA (Hale et al. 2014). Similarly, S. 
thermophilus Csm complex binds complementary ssRNA 100 times tighter than ssDNA 
(Tamulaitis et al. 2014). Together these data support the second model in which the Type 
III effector complex (Cmr or Csm) binds to the nascent transcript (Figure 5.1). Once 
recruited by transcript binding, the ssDNA cleavage activity of the effector complex is 
activated. A likely substrate for this activity being the displaced ssDNA of the displaced 
non-template strand (Samai et al. 2015) of the downstream transcription bubble (Figure 
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7), which has been show by previous foot-printing assays to be more accessible than the 
template-strand in a transcription bubble (Wang & Landick 1997). 
 
The active site for DNA cleavage may vary both between and within Type III-A 
and Type III-B systems. Through mutagenesis we mapped the DNA nuclease activity of 
the Type III-B Cmr complex to the HD motif of Cmr2 (Figure 4.3), as initially predicted 
from sequence analysis (Makarova et al. 2011). The HD domain of the Csm1 protein 
from the Type III-A system of Thermococcus onnurineus was also found to have DNA 
nuclease activity (Jung et al. 2015). This provides a link between the Type III and Type I 
systems as Type I systems also use HD domains, located in Cas3, to destroy their DNA 
targets (Westra et al. 2012; Mulepati & Bailey 2013; Sinkunas et al. 2013). However, in 
the Type III-A system of Staphylococcus epidermidis the HD motif of Csm1 is not 
required for DNA cleavage (Hatoum-Aslan et al. 2014). Instead, the GGDD motif in the 
palm domain of Csm1 is required (Hatoum-Aslan et al. 2014; Samai et al. 2015; Ramia, 
Tang, et al. 2014b). Moreover, some Type III-B systems contain Cmr2 proteins lacking 
HD domains, such as T. thermophilus (Staals et al. 2013). In these organisms the Type 
III-B system may either only target RNA or the GGDD motif may be used for DNA 
cleavage. More structural and biochemical studies are required to clarify the role of these 
two motifs (HD versus GGDD) in the different Type III systems.  
 
Nucleases need to be tightly regulated so they cleave only the intended substrates, 
as any non-specific activity could be deleterious to the cell. The transcript-binding model 
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(Figure 5.1) provides a mechanism for both spatial and temporal regulation of DNA 
cleavage by the Cmr complex. Spatial regulation can be achieved by tethering the 
activated Cmr complex to a specific region of DNA that is actively transcribing, through 
base pairing between the crRNA and transcript. This spatial restraint would ensure that 
activated Cmr complex does not cleave at other transcription bubbles, such as those 
found at transcribing host genes. Thus, spatial regulation may provide a mechanism for 
immunity, specific cleavage of transcribing foreign DNA, rather than cell death, cleavage 
of transcribing host DNA. Targeting antisense transcription of host CRISPR loci, which 
has been observed in several species (Garrett et al. 2015; Hale et al. 2012), appears to be 
prevented by base paring between the 5’-handle of the crRNA and the complementary 
region of the resulting antisense transcript (Figure 4.4). Temporal regulation can be 
achieved by coupling DNA cleavage to the presence of an intact transcript, as once the 
transcript is cleaved the DNA nuclease activity is deactivated (Figure 4.1B). Due to this 
coupling of DNA and RNA cleavage activities, in cells the rate of transcript cleavage 
should to be slower than the rate of DNA cleavage in order for efficient DNA cleavage to 
occur. This isn’t the case in our in vitro experiments as the rate of ssDNA cleavage is 
slower than the rate of ssRNA cleavage, compare lanes 8-10 in Figure 4.5A with lanes 1-
4 in Figure 4.5B. However, in our in vitro assay we use ssDNA oligonucleotides as 
substrates. In cells, we propose that the relevant substrate is the non-template strand of 
the transcription bubble. This substrate may be a better substrate for the Cmr complex 
than ssDNA oligonucleotides and thus may be cleaved at a higher rate. Also, as discussed 
above, by targeting a transcribing region of DNA the Cmr complex is tethered to its DNA 
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substrate by its interactions with the nascent transcript. This tethering would increase the 
effective concentration of the DNA, again likely stimulating the rate of its cleavage. In 
addition to the possible effects on DNA cleavage, the rate of RNA cleavage in the context 
of a transcript emerging from a transcription bubble maybe slower than with a free RNA 
oligonucleotide substrate. Further experiments carefully examining these rates in the 
context of transcription-coupled targeting both in vitro and in vivo will be required to 
provide a complete mechanistic description of the system. 
 
In summary, our studies provide biochemical evidence that the Type III-B system 
cleave ssDNA in the presence of an RNA target complementary to the crRNA. These 
results are consistent with previous results showing the Type III-B system protects cells 
from plasmid transformation in a transcription-coupled manner (Deng et al. 2013). Our 
data further resolves the ambiguity in activities reported for Type III systems and 
supports a unified mechanism for all Type III systems in which DNA nuclease activity is 












Figure 5.1 A model for the mode of action of the Type III-B CRISPR-Cas systems. Once 
RNA polymerase transcribes through the protospacer, the Cmr complex binds to the 
nascent transcript through base pairing with the crRNA. Transcript binding activates the 
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DNA and RNA nuclease activities of the Cmr complex. The DNA nuclease activity of 
the HD domain from Cmr2 cleaves the displaced non-template strand of the transcription 
bubble at sites 3’ of thymidine nucleotides. The RNA nuclease activity cleaves the 
mRNA target stepwise through four sites. Activation of the DNA nuclease activity is 
dependent on the presence of a bound complementary target. Therefore, once the RNA 
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